Spots Global Cancer Trial Database for Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
Official Title: Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer
Study ID: NCT00996983
Interventions
Study Description
Brief Summary: Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.
Detailed Description: The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Istituto Nazionale dei Tumori , Unita Terapia Antalgica, Napoli, , Italy
Contact Details
Name: Arturo Cuomo, M.D.
Affiliation: NCI Naples, Division of Pain Therapy
Role: PRINCIPAL_INVESTIGATOR
Name: Gennaro Russo, M.D.
Affiliation: NCI Naples, Division of Pain Therapy
Role: PRINCIPAL_INVESTIGATOR
Name: Alessandro Morabito, M.D.
Affiliation: NCI Naples, Clinical Trials Unit
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
